Annovis Announces Two Presentations at the CTAD 2025 Conference

Rhea-AI Summary

Annovis (NYSE: ANVS) announced two scientific presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD), December 1–4, 2025 in San Diego.

Presentation P073 covers amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson’s disease dementia patients, presented by Cheng Fang, Ph.D. Presentation P007 describes a double 6/18-month Phase 3 study testing symptomatic and potential disease‑modifying efficacy of buntanetap in Alzheimer’s disease, presented by Maria Maccecchini, Ph.D., President and CEO. Both talks highlight recent biomarker data and cognition findings the company says support buntanetap’s potential disease‑modifying activity.

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 18^th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California.

The presentations will highlight progress across the Alzheimer’s and Parkinson’s programs, with a particular focus on recent biomarker data supporting the potential disease-modifying activity of buntanetap.

Details:

Presentation #1 (P073)

• Title: Amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson’s disease dementia patients
• Presenter: Cheng Fang, Ph.D., Senior VP, Research & Development
• Time: December 1, 3:00 pm – December 2, 5:30 pm
  
  

Presentation #2 (P007)

• Title: Double 6/18-month Phase 3 study to reproduce symptomatic and potentially show disease-modifying efficacy of buntanetap in treating Alzheimer’s disease
• Presenter: Maria Maccecchini, Ph.D., President and CEO
• Time: December 1, 3:00 pm – December 2, 5:30 pm
  
  

“We look forward to attending CTAD, which comes at the perfect moment to share our latest findings on biomarkers and cognition with the scientific community—work we believe will resonate with clinicians, researchers, and industry leaders,” said Maria Maccecchini, Ph.D., President and CEO of Annovis. “Across both disease indications, our biomarker data tell a clear story—buntanetap has the potential to address the root drivers of cognitive decline. These results not only confirm the efficacy of buntanetap seen in our earlier studies but also give us a clearer path forward as we work to bring an effective treatment to patients who urgently need better options.”

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com‍

FAQ

When and where will Annovis (ANVS) present at CTAD 2025?

Annovis will present at CTAD in San Diego during December 1–4, 2025; the two listed presentations occur within that timeframe.

What is the focus of Annovis presentation P073 at CTAD 2025?

Presentation P073 focuses on amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson’s disease dementia patients.

What does presentation P007 (ANVS) describe for the Phase 3 buntanetap study?

Presentation P007 outlines a double 6/18-month Phase 3 design to reproduce symptomatic effects and potentially show disease‑modifying efficacy in Alzheimer’s disease.

Who are the Annovis presenters at CTAD 2025 and their roles?

Cheng Fang, Ph.D., Senior VP R&D, will present P073; Maria Maccecchini, Ph.D., President and CEO, will present P007.

Will Annovis present biomarker data for buntanetap at CTAD 2025?

Yes; both presentations highlight recent biomarker data and cognitive findings related to buntanetap.

How might the CTAD 2025 presentations affect ANVS investors in the near term?

The presentations are intended to disclose biomarker and cognitive data that could inform clinical progress, but no new financial guidance or trial readouts with specific dates were announced.